Federated Hermes
HRTX icon

Federated Hermes’s Heron Therapeutics HRTX Stock Holding History

Federated Hermes’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-110,914
Closed -$221K – 2130
2024
Q3 		$221K Buy
110,914
+60,644
+121% +$145K ﹤0.01% 1466
2024
Q2 		$176K Buy
50,270
+570
+1% +$1.75K ﹤0.01% 1502
2024
Q1 		$138K Buy
+49,700
New +$125K ﹤0.01% 1546
2023
Q1 		– Sell
-15
Closed -$38 – 2178
2022
Q4 		$38 Buy
+15
New +$48 ﹤0.01% 2135
2022
Q3 		– Sell
-280,100
Closed -$781K – 2182
2022
Q2 		$781K Buy
280,100
+280,098
+14,004,900% +$1.12M ﹤0.01% 1237
2022
Q1 		$1K Buy
+2
New +$15 ﹤0.01% 2095
2020
Q2 		– Sell
-25,462
Closed -$299K – 2292
2020
Q1 		$299K Buy
+25,462
New +$479K ﹤0.01% 1502
2018
Q4 		– Sell
-9,298
Closed -$294K – 2244
2018
Q3 		$294K Sell
9,298
-183,380
-95% -$6.83M ﹤0.01% 1557
2018
Q2 		$7.49M Buy
192,678
+100,373
+109% +$3.2M 0.02% 567
2018
Q1 		$2.55M Buy
92,305
+20,708
+29% +$470K 0.01% 866
2017
Q4 		$1.3M Buy
+71,597
New +$1.17M ﹤0.01% 1122
2014
Q4 		– Sell
-375,000
Closed -$3.12M – 1997
2014
Q3 		$3.12M Hold
375,000
– – 0.01% 802
2014
Q2 		$4.62M Buy
+375,000
New +$4.48M 0.01% 665

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Federated Hermes's HRTX Position: Q4 2024 in Review

Federated Hermes sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 110,914 shares — an estimated $221K sold.

Federated Hermes first reported a position in HRTX in Q2 2014 and held it in 13 quarters. The position peaked at $7.49M in Q2 2018. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Federated Hermes reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 110,914 Heron Therapeutics shares in Q4 2024, an estimated $221K.
  • Federated Hermes first reported a position in Heron Therapeutics in Q2 2014 and held it in 13 quarters.
  • Federated Hermes's Heron Therapeutics position peaked at $7.49M in Q2 2018.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.